FRUZAQLA® (fruquintinib) efficacy

FRUZAQLA demonstrated consistent efficacy and safety profile across 2 clinical trials1-3

FRUZAQLA was studied across two phase 3 studies that included more than 1100 patients with metastatic colorectal cancer, FRESCO and FRESCO-2.1-3

In these two clinical studies, the primary endpoint was overall survival, and the secondary endpoints included progression-free survival, objective response rate, disease control rate, duration of response, and safety.1,3 Patients were randomized (2:1) to receive FRUZAQLA 5 mg orally once daily for the first 21 days of each 28-day cycle plus BSC or placebo + BSC.1 Check out the results from FRESCO-2 and FRESCO below.

BSC=best supportive care.

FRESCO-2 Efficacy Results

Learn about the efficacy results from FRESCO-2, a global, double-blind, placebo-controlled study with a heterogenous patient population.

FRESCO-2 Quality of Life Data

Learn more about how Quality of Life was measured in FRESCO-2.

FRESCO Efficacy Results

Learn about the efficacy results from FRESCO, a single-country study of patients with previously treated mCRC.